A Hypoxia-Related miRNA-mRNA Signature for Predicting the Response and Prognosis of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma
Shaoqi Zong,Guokai Huang,Bo Pan,Shasha Zhao,Changquan Ling,Binbin Cheng
DOI: https://doi.org/10.2147/jhc.s454698
2024-03-12
Journal of Hepatocellular Carcinoma
Abstract:Shaoqi Zong, 1, 2, &ast Guokai Huang, 1, 3, &ast Bo Pan, 1, &ast Shasha Zhao, 4 Changquan Ling, 1, 3 Binbin Cheng 1, 3 1 Oncology Department of Traditional Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, 200043, People's Republic of China; 2 Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, People's Republic of China; 3 Faculty of Traditional Chinese Medicine, Naval Medical University, Shanghai, 200043, People's Republic of China; 4 Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China &astThese authors contributed equally to this work Correspondence: Binbin Cheng, Oncology Department of Traditional Chinese Medicine, The First Affiliated Hospital of Naval Medical University, 168 Changhai Road, Shanghai, 200043, People's Republic of China, Email Changquan Ling, Faculty of Traditional Chinese Medicine, Naval Medical University, 800 Xiangyin Road, Shanghai, 200043, People's Republic of China, Email Purpose: Transcatheter arterial chemoembolization (TACE) is commonly used in the treatment of hepatocellular carcinoma (HCC). However, not all patients respond to this treatment. TACE typically leads to hypoxia in the tumor microenvironment. Therefore, we aimed to construct a prognostic model based on hypoxia-related differentially expressed microRNA (miRNAs) in hepatocellular carcinoma (HCC) and to investigate the potential target mRNAs for predicting TACE response. Methods: The hypoxia-related miRNAs (HRMs) were identified in liver cancer cells, then global test was performed to further select the miRNAs which were associated with recurrence and vascular invasion. A prognostic model was constructed based on multivariate Cox regression analysis; qRT-PCR analysis was used to validate the differentially expressed miRNAs in HCC cell lines under hypoxic condition. We further identified the putative target genes of the miRNAs and investigate the relationship between the target genes and TACE response, immune cells infiltration. Results: We established a HRMs prognostic model for HCC patients, containing two miRNAs (miR-638, miR-501-5p), the patients with high-HRMs score showed worse survival in discovery and validation cohort; qRT-PCR analysis confirmed that these two miRNAs are up-regulated in hepatoma cells under hypoxic condition. Furthermore, four putative target genes of these two miRNAs were identified (ADH1B, CTH, FTCD, RCL1), which were significantly associated with TACE response, immune score, immunosuppressive immune cells infiltration, PDCD1 and CTLA4. Conclusion: The HCC-HRMs signature may be utilized as a promising prognostic factor and may have implications for guiding TACE and immune therapy. Keywords: hypoxia, miRNA, signature, hepatocellular carcinoma, prognosis Primary liver cancer (PLC), the incidence ranks sixth and the cancer-related mortality rate is the third leading among all malignant tumors in the world. 1 Hepatocellular carcinoma (HCC) is the most common type of PLC, with a 5-year-survival rate of less than 21%. 2 Surgical resection is generally considered the mainly radical treatment for HCC. 3,4 However, resection is only possible in a small proportion of patients because of the advanced tumor stages at the time of diagnosis and poor hepatic function. Transarterial chemoembolization (TACE) is recommended as the first-line treatment for intermediate-stage HCC. 5 In addition, clinical studies have reported that adjuvant TACE prolongs the overall survival (OS) and recurrence-free survival (RFS) in patients with HCC after surgical resection. 6,7 With a treatment-related mortality rate of 40% of patients do not respond to this therapy, highlighting the importance of developing an effective biomarker for predicting the survival benefit of TACE. TACE blocks the blood supply to the tumor and thereby aggravates local hypoxia, 8 then promoting cancer growth, metastasis, 9–11 and leading to poor prognosis. Rhee et al reported that hypoxia related markers could predict TACE resistance and result in poor outcome in HCC; 12 Therefore, it is necessary to develop biomarkers that can predict the response and prognosis based on hypoxia-rela -Abstract Truncated-
oncology